We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Key Witness Against Morning Sickness Drug Faces Scientific Fraud Charges

Andrew Skolnick
JAMA. 1990;263(11):1468-1473. doi:10.1001/jama.1990.03440110020003.
Text Size: A A A
Published online


WILLIAM McBRIDE, MD, the Australian obstetrician many credit as being among the first to notice the association between thalidomide and birth defects (see accompanying article), is now facing charges of scientific fraud and professional misconduct before an Australian medical tribunal.

Some of the 15 charges against him concern his efforts to show that the anti-morning sickness drug Bendectin is also teratogenic. According to the New South Wales State Department of Health's Complaints Unit in Sydney, McBride is accused of fabricating data in a published study and falsely testifying in US federal courts about his research. His testimony played a key role in many of the lawsuits against Merrell Dow Pharmaceuticals, Inc, Cincinnati, Ohio, which manufactured Bendectin, the only drug approved by the US Food and Drug Administration for the treatment of nausea during pregnancy.

Responding to the onslaught of hundreds of lawsuits, Merrell Dow halted production of its anti-morning sickness


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.